Pacific Excel Wealth Advisors Inc. Purchases Shares of 2,952 Johnson & Johnson $JNJ

Pacific Excel Wealth Advisors Inc. acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 2,952 shares of the company’s stock, valued at approximately $750,000.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Greenberg Financial Group acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at about $954,000. World Investment Advisors boosted its holdings in Johnson & Johnson by 19.6% in the 4th quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after purchasing an additional 26,450 shares during the period. Benchmark Financial LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at about $554,000. Robinhood Asset Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $11,853,000. Finally, Principal Financial Group Inc. raised its position in shares of Johnson & Johnson by 0.8% in the fourth quarter. Principal Financial Group Inc. now owns 3,410,177 shares of the company’s stock valued at $705,736,000 after buying an additional 28,370 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.3%

NYSE JNJ opened at $255.26 on Wednesday. The business has a fifty day moving average price of $246.74 and a two-hundred day moving average price of $239.05. The stock has a market capitalization of $615.15 billion, a PE ratio of 29.58, a PEG ratio of 2.41 and a beta of 0.24. Johnson & Johnson has a fifty-two week low of $169.65 and a fifty-two week high of $274.90. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter in the previous year, the firm earned $2.77 EPS. Johnson & Johnson’s revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts expect that Johnson & Johnson will post 11.69 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is 62.11%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on JNJ shares. Bank of America increased their price target on Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a research report on Friday, July 10th. Sanford C. Bernstein upped their target price on Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research report on Wednesday, April 15th. TD Cowen increased their target price on Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Morgan Stanley boosted their price target on Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a research note on Thursday, July 16th. Finally, Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $267.48.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.16% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA authorization opens a new growth avenue: The FDA authorized J&J’s OTTAVA robotic surgical system, marking the company’s entry into surgical robotics. Investors view the platform as a potentially meaningful long-term growth driver and a way to diversify beyond pharmaceuticals and medical devices. Johnson & Johnson Gets FDA Nod for OTTAVA
• Positive Sentiment: Strong oncology performance supports earnings growth: Darzalex, Erleada and newer cancer treatments drove solid second-quarter oncology growth, reinforcing expectations that Innovative Medicine can offset pressure from products facing patent expirations. J&J recently exceeded quarterly EPS and revenue estimates and reaffirmed fiscal 2026 EPS guidance of $11.60-$11.75. J&J’s Strong Q2 Oncology Performance Fuels Future Growth Hopes
• Positive Sentiment: Higher analyst valuation: Wells Fargo raised its JNJ price target from $272 to $282 and maintained an Overweight rating, suggesting further upside based on the company’s earnings outlook and growth initiatives. Wells Fargo price-target report
• Neutral Sentiment: Leadership transition announced: Innovative Medicine chairman Jennifer Taubert will retire after more than 21 years with J&J. Tom Cavanaugh will succeed her as executive vice president and worldwide chairman in September. Taubert oversaw the division’s expansion to more than $60 billion in annual revenue, while the transition creates some execution uncertainty. Johnson & Johnson leadership change
• Neutral Sentiment: Competitive concerns appear limited: An analyst covering Intuitive Surgical characterized OTTAVA as a potential growth catalyst rather than a major competitive threat, reducing concerns that J&J’s entry will immediately disrupt the established robotics market. Analyst commentary on OTTAVA

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.